Serotonin synthesis, release and reuptake in terminals: a mathematical model by Best, Janet et al.
RESEARCH Open Access
Serotonin synthesis, release and reuptake in
terminals: a mathematical model
Janet Best
1*, H Frederik Nijhout
2, Michael Reed
3
* Correspondence:
jbest@math.ohio-state.edu
1Department of Mathematics,
The Ohio State University,
Columbus, OH 43210 USA
Abstract
Background: Serotonin is a neurotransmitter that has been linked to a wide variety
of behaviors including feeding and body-weight regulation, social hierarchies,
aggression and suicidality, obsessive compulsive disorder, alcoholism, anxiety, and
affective disorders. Full understanding of serotonergic systems in the central nervous
system involves genomics, neurochemistry, electrophysiology, and behavior. Though
associations have been found between functions at these different levels, in most
cases the causal mechanisms are unknown. The scientific issues are daunting but
important for human health because of the use of selective serotonin reuptake
inhibitors and other pharmacological agents to treat disorders in the serotonergic
signaling system.
Methods: We construct a mathematical model of serotonin synthesis, release, and
reuptake in a single serotonergic neuron terminal. The model includes the effects of
autoreceptors, the transport of tryptophan into the terminal, and the metabolism of
serotonin, as well as the dependence of release on the firing rate. The model is
based on real physiology determined experimentally and is compared to
experimental data.
Results: We compare the variations in serotonin and dopamine synthesis due to
meals and find that dopamine synthesis is insensitive to the availability of tyrosine
but serotonin synthesis is sensitive to the availability of tryptophan. We conduct
in silico experiments on the clearance of extracellular serotonin, normally and in the
presence of fluoxetine, and compare to experimental data. We study the effects of
various polymorphisms in the genes for the serotonin transporter and for tryptophan
hydroxylase on synthesis, release, and reuptake. We find that, because of the
homeostatic feedback mechanisms of the autoreceptors, the polymorphisms have
smaller effects than one expects. We compute the expected steady concentrations of
serotonin transporter knockout mice and compare to experimental data. Finally, we
study how the properties of the the serotonin transporter and the autoreceptors give
rise to the time courses of extracellular serotonin in various projection regions after a
dose of fluoxetine.
Conclusions: Serotonergic systems must respond robustly to important biological
signals, while at the same time maintaining homeostasis in the face of normal
biological fluctuations in inputs, expression levels, and firing rates. This is
accomplished through the cooperative effect of many different homeostatic
mechanisms including special properties of the serotonin transporters and the
serotonin autoreceptors. Many difficult questions remain in order to fully understand
how serotonin biochemistry affects serotonin electrophysiology and vice versa, and
how both are changed in the presence of selective serotonin reuptake inhibitors.
Mathematical models are useful tools for investigating some of these questions.
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Traditionally, serotonin (5-HT) has been associated to a wide variety of behaviors
including feeding and body-weight regulation, social hierarchies, aggression and suicid-
ality, obsessive compulsive disorder, alcoholism, anxiety, and affective disorders[1]. In
addition, 5-HT has been linked to motor system function[2], sleep-wake cycles[3], cir-
cadian rhythms[4], respiratory stability[5], embryonic development[6], and reward pro-
cessing[7]. Not surprisingly, the 5-HT neurons in the nuclei originally classified by
Dalhstrom and Fuxe[8] project to a large variety of regions of the central nervous sys-
tem including spinal cord, cerebellum, frontal cortex, hypothalamus, hippocampus,
striatum, and a bewildering variety of 5-HT receptors have been identified [9]. A huge
body of research on genomics, anatomy, neurochemistry, electrophysiology, and beha-
vior has provided a wealth of information on serotonergic systems, but the causal
mechanisms of serotonergic function, both normal and in the presence of various dis-
orders and pharmacological agents, remain largely unknown.
Polymorphisms in the serotonin reuptake transporter (SERT) gene have been asso-
ciated with depression and other mood disorders[10-13] and may be associated with
anxiety[14], autism[15], and suicidality[16,17]. Polymorphisms in the tryptophan hydro-
xylase gene have been associated with unipolar[18] and bipolar disorder[19]. Further-
more, variations in gene expression very likely play a role in the regulation of
serotonergic systems both normally and in response to selective serotonin reuptake in-
hibitors(SSRIs). SERTs are downregulated in the presence of SSRIs [20,21], 5-HT1A
autoreceptor expression levels differ in different brain regions[22], and 5-HT1A mRNA
levels are affected by gonadal hormones [23].
Because of efforts to understand the modes of action of SSRIs, the neurochemistry of
serotonin has received much attention. Serotonin is synthesized in serotonergic term-
inals from tryptophan, which competes with tyrosine and the branched chain amino
acids for transport across the blood-brain barrier[1,24]. Autoreceptors play important
roles in the regulation of 5-HT chemistry. For example, 5-HT1B autoreceptors on
terminals decrease synthesis and release when extracellular 5-HT rises and 5-HT1A
autoreceptors affect firing rates in the dorsal raphe nucleus[25]. In addition, these reg-
ulatory mechanisms are themselves regulated by dynamic changes in autoreceptor
expression levels[26]. Serotonin acts both in one-to-one neural signaling and as a neu-
romodulator, via volume transmission, of the effects of other neurotransmitters[1,27].
Each of these facts plays an important role in neuropsychiatry and neuropharmacology.
The electrophysiology of serotonergic signaling is related both to neurochemistry and
to behavior. The classical experiments of Jacobs on cats[28] showed that the patterns
of firing of nucleus centralis superior serotonergic neurons correspond to different
sleep-wake states. 5-HT modulates motor firing patterns[2] and motor behavior[29,30].
Autoreceptors affect the inhibition of CA3 hippocampal pyramidal neurons caused by
stimulating the ascending serotonergic pathways[31,32]. 5-HT increases the firing rates
of histaminergic neurons in the hypothalamic tuberomammillary nucleus[33], inhibits
the firing of somatosensory cortical neurons[34], and can inhibit or excite neurons in
the ventromedial nucleus of the hypothalamus[35]. It has been proposed that 5-HT
activates the hypothalamic-pituitary-adrenal axis by stimulating production of cortico-
tropin-releasing hormone[36]. 5-HT influences dopaminergic signaling[37,38] and may
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ally, dopamine was thought to be the primary neurotransmitter involved in reward
processing, but recent work suggests a strong role for 5-HT[7]. Thus, the neurochem-
istry and electrophysiology affect each other, both affect behavior, and both are
affected, of course, by neuronal morphology, which is itself changeable.
Even this brief discussion shows why understanding the casual mechanisms in sero-
tonergic signaling is a challenging problem. Not only does one have to understand
mechanism and function on four different levels, genomic, biochemical, electrophysio-
logical, and behavioral, but changes on each level affect function on the other three
levels, and this makes the interpretation of experimental and clinical results very diffi-
cult. In addition, the brain is not fixed, but dynamical changes on different time scales
are happening at all four levels. Mathematical models can play an important role
because they allow one to study explicitly the simultaneous effects of all the interac-
tions in a large complex system. Ideas and hypotheses can then be tested by in silico
experimentation, that is, by computer simulations of the mathematical model. Our
main interest is to understand how the biochemistry of 5-HT (synthesis, release, reup-
take) is regulated and how the biochemistry affects the electrophysiology and vice
versa. As a first step, we present in this paper a model of 5-HT biochemistry in seroto-
nergic terminals.
The model includes (see Figure 1): uptake of tryptophan across the blood-brain bar-
rier and transport into terminals; synthesis of 5-HT by tryptophan hydroxylase (THP)
and aromatic amino acid decarboxylase (AADC); transport of 5-HT into a vesicular
compartment by the monamine transporter (MAT); release of 5-HT into the extracel-
lular space depending on firing rate; reuptake via the SERTs; regulation by the autore-
ceptors. As much as possible, the model is based on real physiology that has been
determined experimentally. It is worthwhile to say at the outset that there is no such
thing as “the serotonergic terminal"; important parameters (like SERT and autoreceptor
densities) vary in different projection regions and this variation is likely to be related to
function. Our main purpose is to use the model as a platform for in silico experimen-
tation that sheds light on the complex regulatory mechanisms of serotonergic signal-
ing. Some results of some simulations with the model have previously appeared
elsewhere [40].
Mathematical methods have been used by a variety of authors to understand seroto-
nergic signaling. The serotonergic model presented in this paper is conceptually similar
to the dopaminergic model presented in [41]; both models were inspired by the origi-
nal model of Justice et al. [42] for a dopaminergic terminal. Many studies use statistical
methods to identify associations between variables on different levels of the serotoner-
gic system. Cohen and colleagues used theoretical and experimental methods to show
how 5-HT modulates the frequency and phase lag of bursting in lamprey spinal cord
[2,43]. Butera showed by modeling how 5-HT affects the bursting behavior of neuron
R15 in Aplysia [44]. Waggoner and colleagues introduced a three state stochastic
model for the serotonin dependence of egg laying in a nematode[45]. Bunin et al.[46]
and Daws et al.[47] used mathematical models and data to compute apparent values of
the Michaelis-Menten constants Km and Vmax for the SERTs in different projection
regions. Venton et al.[48] used experiments and mathematical models to show that the
extracellular space is well-mixed during tonic firing but not during burst firing. Kim
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mRNA of serotonin N-acetyltransferase is essential for its circadian rhythm. Tanaka
et al.[49] used a mathematical model to show that 5-HT controls the time scale of
reward prediction by differentially regulating activities in the striatum. Dayan and Huys
[50] used a Markov model to study the effects of 5-HT on how the predictions of
future outcomes lead to behavioral inhibition, suppression, and withdrawal and created
a computational model to investigate 5-HT in affective control[51]. Stoltenberg and
Nag[52] used a dynamical systems model to go directly from genes to behavior.
Methods
The mathematical model consists of nine differential equations for the variables listed
in Table 1. The differential equations corresponding to the reactions diagrammed in
Figure 1 follow in Table 2. Reaction velocities or transport velocities begin with a
Figure 1 Steady state concentrations and fluxes. The figure shows the reactions in the model. The
rectangular boxes indicate substrates and blue ellipses contain the acronyms of enzymes, transporters, and
autoreceptors; steady state values in the model are indicated. Full names of the substrates are given in
Table 1. Names of enzymes and transporters are as follows: Trpin, neutral amino acid transporter; DRR,
dihydrobiopterin reductase; TPH, tryptophan hydroxylase; AADC, aromatic amino acid decarboxylase; MAT,
vesicular monoamine transporter; SERT, 5-HT reuptake transporter; auto, 5-HT autoreceptors; MAO
monoamine oxidase; ALDH, aldehyde dehydrogenase. Removal means uptake by capillaries or glial cells or
diffusion out of the system.
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script. For example, VTPH(trp, bh4, e5ht) is the velocity of the tryptophan hydroxylase
reaction and it depends on the concentrations of its substrates, trp and bh4, as well as
e5ht (via the autoreceptors). Below we discuss in detail the more difficult modeling
issues and reactions with non-standard kinetics. Table 3 gives the parameter choices
and references for reactions that have Michaelis-Menten kinetics in any of the follow-
ing standard forms:
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for unidirectional, one substrate, unidirectional, two substrates, and bidirectional, two
substrates, two products, respectively.
Table 1 gives the abbreviations used for the variables throughout. We use lower case
italic abbreviations in the differential equations and other formulas so that they are
easier to read. Full names for the enzymes appear in the legend to Figure 1.
Tryptophan and the tryptophan pool
Serum tryptophan concentrations have been measured in humans and other mammals
both before and after meals with different protein composition. A range of 53-85 μM
was found in [53] and a range of 61-173 μM was found in [54]. We take as our base-
line the value of 96 μM found by Fernstrom in fasted rats [24]. During the experiments
with our model in Results A, the serum values of tryptophan were varied correspond-
ing to meals.
Tryptophan is transported across the blood-brain barrier by the L-transporter and is
then taken up by serotonergic neuron terminals [55]. We simplify these two steps into
Table 1 Names used for Variables
in equations in text full name
bh2 BH2 dihydrobiopterin
bh4 BH4 tetrahydrobiopterin
trp Trp tryptophan
btrp serum Trp serum tryptophan
5htp 5-HTP 5-hydroxytryptamine
c5ht cytosolic 5-HT cytosolic serotonin
v5ht vesicular 5-HT vesicular serotonin
e5ht extracellular 5-HT extracellular serotonin
5hiaa 5-HIAA 5-hydroxyindoleacetic acid
trp–pool the tryptophan pool the tryptophan pool
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6a single step with the kinetics of the L-transporter. Choosing the right Km for the L-
transporter is complicated by two issues. First, the majority of tryptophan in the serum
is not free but bound to albumin. Second, the other neutral and branched chain amino
acids compete for the same transporter, so the effective Km depends on the concentra-
tions of these other amino acids. Partridge [56] measured a Km = 190 μM with respect
Table 3 Kinetic Parameters (μM, μM/hr,/hr)
velocity parameter model value literature value references
VAADC aromatic amino acid decarboxylase
km 160 160 [121]
Vmax 400 *
VSERT serotonin transporter
km .17 0.05-1 [1,46,47]
Vmax 8000 *
VDRR dihydropteridine reductase
Kbh2 100 4-754 [122,123]
KNADPH 75 29-770 [124-126]
V
f
max
5000 *
Kbh4 10 1.1-17 [125,127]
KNADP 75 29-770 [124-126]
V
b
max
3*
VMAT vesicular monoamine transporter
Km .198 .123-.253 [65,66]
Vmax 3500 *
kout 40 *
VTPH tryptophan hydroxylase
Ktrp 40 40 [64]
Kbh4 20 20 [64]
Vmax 400 *
Ki (substrate inhibition) 1000 970 [64]
Vtrpin neutral amino acid transporter
Km 64 64 [55]
Vmax 400 *
trp ↔ trp-pool
k1 6*
k-1 0.6 *
catabolism and diffusion
ktrp
catab 0.2 *
Vmax
catab c ht () 5 1000 *
Km
catab c ht () 5 95 94-95 [81,82]
Vmax
catab e ht () 5 1000 *
Km
catab e ht () 5 95 94-95 [81,82]
khiaa
catab 1 .82 [83]
ktrp pool
catab
−
0.2 *
krem 400 *
* see text
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serum tryptophan. We will use the effective Km = 330 μM in the presence of other
amino acids given in Kilberg [55]. We choose Vmax = 700 μM/hr so that, in our
model, the rate of transport into the brain (159 μM/hr) closely matches that found by
Kilberg (159 μM/hr).
Intracellular tryptophan is used in a large number of biochemical pathways and, of
course, in protein synthesis, which accounts for about half the use of tryptophan [58].
Protein breakdown and a variety of biochemical pathways are intracellular sources of
tryptophan. Overall, about 2% of ingested tryptophan is used for the synthesis of sero-
tonin [59,60]. These numbers give some crude upper and lower bounds for the percen-
tage of intracellular tryptophan that goes to the synthesis of serotonin, but accurate
estimates are not known. In dopaminergic neurons about 90% of tyrosine goes to pro-
tein synthesis and other pathways and about 10% to dopamine synthesis [61-63], so it
seems reasonable to make a similar estimate for tryptophan. We let the variable trp-
pool represent all the other intracellular sin k sa n ds o u r c e so ft r y p t o p h a na n da s s u m e
that intracellular tryptophan, trp, and trp-pool can be interconverted into each other:
trp trp pool
k
k
1
1 −
←→ ⎯⎯ ⎯ . (4)
We choose the rate constants k1 =6μM/hr and k-1 =. 6μM/hr so that trp-pool is
approximately 10 times as large as trp:
Tryptophan hydroxylase
Tryptophan (trp) and tetrahydrobiopterin (bh4) are converted by tryptophan hydroxy-
lase (TPH) into 5-hydroxytryptamine (5htp) and dihyro-biopterin (bh2). The velocity of
the reaction, VTPH, depends on trp, bh4, and extracellular 5-HT (e5ht) via the autorecep-
tors. We take the basic kinetics from [64] with Ktrp =4 0μM, Kbh4=2 0μM. TPH exhibits
substrate inhibition but it is quite weak, Ki = 1000. The second term in the velocity
equation below, which represents the effect of extracellular 5-HT on synthesis rate, is
discussed in detail below under “autoreceptors.” The constants are chosen so that at the
normal steady state (e5ht = .000768 μM) this factor is equal to one, so the normal steady
state is the same with and without the autoreceptors. This allows us to compare how the
system changes with and without the autoreceptors when we perturb the system by
changing enzyme properties, neuron firing rates, or transporter properties.
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Storage, release, and reuptake of serotonin
The 5-HTP produced by the TPH reaction is rapidly decarboxylated by the aromatic
amino acid decarboxylase (AADC) to produce cytosolic serotonin. We take the
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MAT, rapidly transports 5-HT into vesicles. We take the Km of the transporter to be
0.198 μM as found in [65], which is consistent with the values in [66]. We choose the
Vmax so that the concentration of cytosolic serotonin is very low. The experiments in
[67] and the calculations in [68] in the case of dopamine suggest strongly that there is
transport from the vesicles back into the cytosol, either dependent or independent of the
MAT and it is likely that the same is true of serotonin [69]. We assume this transport is
linear with rate constant, kout, chosen so that the vast majority (i.e., 98%) of the cellular
serotonin is in the vesicular compartment. For simplicity we are assuming that the vesi-
cular compartment is the same size as the non-vesicular cytosolic compartment. This
assumption is unimportant since we take the cytosol to be well-mixed and we are not
investigating vesicle creation, movement toward the synapic cleft, and recyling where
geometry and volume considerations would be crucial. Of course, if we took the volume
of the vesicular compartment to be much smaller than the volume of the cytosolic com-
partment, say 1 to 100, then the ratio of vesicular 5-HT concentration to cytosolic 5-HT
concentration would approach the value of 10
4 suggested in [69].
In our model, vesicular 5-HT (v5ht in the equations) is removed from the vesicles
and put into the synaptic cleft, where it becomes e5ht,b yt h et e r mrelease(e5ht) fire(t)
vda(t) in the differential equations for v5ht and e5ht (see the differential equations
above). fire is a function of time in some of our in silico experiments, for example in
Results B and C where we investigate pulse experiments and in Results E where we
consider the effects SSRIs. However, for determining our baseline steady state we take
fire =1μM/hr, which means that vesicular serotonin is released at a constant rate
such that the entire pool turns over once per hour. The term release(e5ht)r e p r e s e n t s
the effect of e5ht on release via the autoreceptors and is discussed below. The pro-
cesses by which vesicles are created, move to the synapse, and release their serotonin
are complicated and interesting [67,70-72], but are not included in this model.
Extracellular serotonin has three fates. It is pumped back into the cytosol by the
SERTs; it is catabolized; it is removed from the system. The Km =. 1 7μMf o rt h e
SERTs is taken from [46]. As we will discuss later, the Vmax will vary considerably
from one projection region to another because the density of SERTs varies by at least
a factor of 5. For our baseline case, we take Vmax = 4700 μM/hr which is in the middle
of the range, 2052-6480 μM/hr, found in [46]. The function fluox(t) that multiplies the
term VSERT in the differential equations for the variables v5ht and e5ht is the fraction
of SERTs that remain unblocked in the presence of an SSRI. In the absence of SSRIs,
fluox(t) = 1. Catabolism and removal are discussed below.
Autoreceptors
It has been understood since the 1970s and 1980s that terminal autoreceptors (5-
HT1B) sense the extracellular 5-HT concentration (e5ht in the equations). When e5ht
goes up, they inhibit both the synthesis of 5-HT and the release of 5-HT from the vesi-
cles into the synaptic cleft and when e5HT goes down they facilitate synthesis and
release [9,25,73]. Thus e5ht provides a kind of end-point feedback for the entire sero-
tonergic system from tryptophan in the serum to e5HT in the extracellular space. It is
also known [74] that autoreceptors modulate reuptake, but this effect is not included
in the model. Extracellular 5-HT or autoreceptor agonists can decrease synthesis by
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can increase synthesis by as much as 40-60% [77,79]. These and many other experi-
ments are often conducted with large amounts of agonists or antagonists, which leaves
open the question of what range of extracellular 5-HT causes these effects. Experi-
ments on rats [76,80] showed that cocaine administration elevates extracellular 5-HT
by factors of 2 to 5 and that such elevation has a large depressive effect on 5-HT
synthesis, so it is reasonable to assume that synthesis is significantly affected by
changes in e5ht over less than an order of magnitude. The second term in the formula
for VTPH above contains the effect of e5ht on synthesis. When extracellular 5-HT has
its steady state value of 0.768 nM the factor is equal to 1. As extracellular 5-HT
declines towards 0, the factor increases to 1.5 and as extracellular 5-HT increases the
factor declines to 0.5 (almost reaching that level when e5ht = 3 nM). Thus facilitation
of synthesis can be as much as 50% and inhibition of synthesis can be as much as 50%
and most of the effect is between 0-3 nM of extracellular 5-HT.
Similarly, many experiments have shown that release of vesicular serotonin can be
inhibited by increased e5ht via the autoreceptors or facilitated if e5ht goes down. For
example, Gothert found that release can be inhibited 65% and facilitated by 50-60%
[77]. It is not certain from the experiments over what range of e5ht this effect takes
place. We will assume a modest effect over a relatively small range. The factor release
(e5ht) descends linearly from 1.5 at e5ht =0t o1 . 0a te5ht = .000768 μM, the normal
steady state. Then the factor descends linearly from 1.0 at e5ht = .000768 μMt o0 . 4a t
e5ht = .0023 μM. For e5ht > .0023, release(e5ht) remains constant at 0.4. Thus, the
maximal facilitation is 50% and the maximal inhibition is 60% and the effect takes
place over the range 0 - 2.3 nM of extracellular 5-HT.
Metabolism and removal of serotonin
Serotonin is metabolized by monoamine oxidase (MAO) and aldehyde dehydrogenase
(ALDH) to 5-hydroxyindoleacetic acid (5 - hiaa). In our simple model we are not
investigating the details of catabolism, only in how c5ht and e5ht are removed from
the system, so we combine these two steps into one and use the Km =9 5μM deter-
mined in [81,82]. The rate constant for the removal of 5hiaa was measured to be 0.82
± .06 in [83]; we take it to be 1/hr. This results in a model steady state concentration
of 5hiaa =5 . 2 2μM. The ratio of 5-HIAA to 5-HT was measured to be around 1 in
[84] and in the range 1-3 in [85]. Since tissue content of 5-HT in different brain
regions is roughly 2-3 μM [86-88], the concentration 5hiaa = 5.22 μM is reasonable.
In our model the extracellular space is a single compartment. One should think of it
as the part of the entire extracellular space corresponding to this particular synapse.
Of course, if we had many model synapses, the e5ht from one will diffuse into the
extracellular compartment of another (volume transmission). We are assuming for
simplicity that the extracellular space is well-mixed, that is, we are ignoring diffusion
gradients between different parts of the extracellular space. Venton et al. [48] have
shown in the case of dopamine, using a combination of experiments and modeling,
that the extracellular space is well-mixed during tonic firing but that substantial gradi-
ents exists between “hot spots” of release and reuptake and the rest of the extracellular
space during and just after episodes of burst firing. The term krem(e5ht) in the differen-
tial equation for e5ht represents removal of e5ht though uptake by glial cells, uptake by
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base case, we chose krem = 400/hr. At steady state in the base case (see Figure 1), 21.4
μM/hr of v5ht is put into the extracellular space, 21.1 μM/hr is put back into the cyto-
sol by the SERTs, 0.1 μM/hr is catabolized in the extracellular space, and 0.3 μM/hr is
removed. Thus the effect of the removal term is small at steady state but it plays a big-
ger role when large amounts of v5ht are dumped into the extracellular space, for
example in the pulse experiments described in Results B.
Fluoxetine dosing
In part E of the results we use the model to investigate the results of giving a dose of
the SSRI fluoxetine. The dose is represented in the model by changing the fraction of
SERTs that are unblocked at any given time. The resulting function, fluox(t), multiplies
VSERT in the differential equations for c5ht and e5ht. Since we give the dose at 1 hour,
fluox(t)=1i ft ≤ 1, and for t ≥ 1,
fluox t
t
t
e
t ()
(. )( )
.( )
.
() =−
−
+−
⋅
−− 1
95 1 2
04 1 2
13 7 (6)
The half-life of fluoxetine is quite long; 1-4 days is reported in [89]. The number 37
appearing in the exponential corresponds to a half-life of fluoxetine of a little more
than a day.
Steady state concentrations and velocities
Figure 1 shows the concentrations of all of the variables and the reaction and transport
velocities at steady state.
The rate of tryptophan uptake from the serum is 159 μM as found by [55]. The cel-
lular tryptophan concentration, 20.6 μM, is in the range found in most studies [86,90].
The rate of the TPH and AADC reactions, which must be equal at steady state, is in
the middle of the range of values for 5-HT synthesis reported in the literature, 2.4
μM/hr [91] to approximately 13 μM/hr [83,92].
It is known that the cytosolic concentrations of 5-HTP and 5-HT are quite low.
Fernstrom [86] measured 2 μM for 5-HTP and it is 2.26 μM in the model. It is very
diffcult to get reliable estimates for cytosolic 5-HT since tissue measurements include
the vesicles where the concentration is known to be very high [69]. In our model cyto-
solic 5-HT = 0.5 μM at steady state, a very low value since cytosolic 5-HT is rapidly
pumped into the vesicular compartment by the monoamine transporter where the con-
centration is 21.45 μM. The vesicular compartment turns over once an hour at steady
state releasing 21.45 μM/hr into the extracellular space. There, 21.13 μM/hr is put
back into the cytosol by the SERTs, 0.3 μM/hr is removed from the system by uptake
by glial cells or blood vessels or simply diffusion out of the tissue, and 0.008 μM/hr is
catabolized.
Most catabolism of 5-HT happens in the cytosol since the extracellular concentra-
tions of 5-HT are so low. Of course, the cytosolic and extracellular catabolism rates
plus the rate of removal must add up to the synthesis rate 5.6 μM/hr. As explained
above, the concentration of 5hiaa = 5.22 μM is reasonable [84,85].
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computed using the stiff ODE solver in MATLAB.
Results
A. The effect of meals on dopamine and serotonin
Since the early work of Fernstrom [93,94] it has been generally thought that dopamine
synthesis is not very sensitive to tyrosine availability but that serotonin synthesis is sensi-
tive to the availability of tryptophan [1]. We have previously constructed a model of
dopamine (DA) synthesis, release, and reuptake in dopaminergic terminals [41], so we
can compare and contrast the effects of meals on synthesis in dopaminergic and seroto-
nergic terminals. The model results are displayed in Figure 2, where Panel A shows the
blood amino acid concentrations, Panel B the cellular DA and 5-HT concentrations,
Panel C the rates of the TH and TPH reactions, and Panel D the concentrations of DA
and 5-HT in the extracellular space, during a 24 time period with three meals. In each
case the y-axis indicates percent of normal. The overall conclusion is clear: there is
much more variation in the 5-HT than the DA concentrations and synthesis rates. To
explain why the curves look the way they do, we shall discuss each panel in turn.
It is known that blood amino acid concentrations vary dramatically depending on
meal content [53-55] and also on the sequence of meals with different content [24].
During a 24 hour period the plasma amino acid concentration can vary as much as a
factor of 6 but more typically varies by a factor of 2 to 4 [54]. The amino acid curves
in the blood in Panel A of Figure 2 were produced by a simple model that assumes
three hours of input corresponding to each meal and a relaxation time back to normal
of about 6 hours after the beginning of each meal [53]. For the purpose of these model
experiments we assume that the amino acid in the blood is either tyrosine or
tryptophan.
Panel B shows the intracellular tyrosine and tryptophan concentrations in the dopa-
minergic and serotonergic terminals. These large swings in substrate availability corre-
spond to what is seen experimentally; for example, Fernstrom found [95] that brain
tyrosine can double after a meal. But why are the oscillations of tryptophan larger than
the oscillations of tyrosine? In our model, the tyrosine input into the DA terminal is
241 μM/hr and the tryptophan input into the 5-HT terminal is 159 μM/hr correspond-
ing to the experiments reported in [55]. However, the steady concentrations of tyrosine
and tryptophan are 126 μMa n d2 1μM, respectively. Thus the tryptophan concentra-
tion is much smaller and has a much larger input and removal rate relative to its con-
centration than does tyrosine. This is why the percentage change due to meals is much
larger in the case of tryptophan. This also explains why the tyrosine peaks increase
from meal to meal, while the tryptophan peaks are all the same height because trypto-
phan returns almost to baseline before the next meal.
Panel C shows the velocities of the TH and TPH reactions during the 24 hour per-
iod. Despite large swings in tyrosine availability, the TH velocity remains almost con-
stant over the 24 hour period because the reaction is running at near saturation due to
the fact that the normal tyrosine concentration is well above the Km for tyrosine,
which is 46 μM in our DA model. In fact, as is clear from the graphs, the rate of the
TH reaction actually goes down as tyrosine rises beyond about 100 μM. This is
because TH shows substrate inhibition [96]. In contrast, the oscillations in the TPH
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well below the Km of TPH for tryptophan (40 μM in the model). Thus the rate of the
TPH reaction is very sensitive to tryptophan availability. TPH also shows substrate
inhibition but it is quite weak and only has an effect at very large (perhaps
Figure 2 The effect of meals on brain DA and 5-HT. Panel A shows the blood concentration over a 24
hour period of either tyrosine or tryptophan due to three meals at 7 am, 12 pm and 6 pm. Panel B shows
the tyrosine and tryptophan concentrations in dopaminergic and serotonergic synaptic terminals. Panel C
shows the velocities of the TH and TPH reactions over the same 24 hour period. Panel D shows the
extracellular DA and 5-HT concentrations. The vesicular stores of DA and 5-HT (not shown) vary like the
extracellular concentrations in Panel D. All calculations for DA were done using the mathematical model
described in [41] and the calculations for 5-HT were done using the mathematical model in this paper.
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cance of substrate inhibition elsewhere [40,97].
Panel D shows the extracellular concentrations of DA and 5-HT over the 24 hour
period. The DA concentration varies very little while the 5-HT concentration varies by
about 10%. The vesicular stores of DA and 5-HT (not shown) vary similarly in the
terminals; since most DA and 5-HT is in these stores, this is what one would see if
one measured brain DA or brain 5-HT. Note that we assume in these model calcula-
tions that both the dopaminergic and the serotonergic neuron are firing at their tonic
rates. Thus these curves give the background concentrations due to tonic firing; burst
firing for short periods of time will give significant temporary deviations. Since 5-HT is
thought to be an appetite suppressant [1], it makes sense that extracellular 5-HT
should rise during and after meals.
B. Release and Reuptake
A number of studies have examined the release of serotonin and reuptake from the
extracellular space. Bunin et al. [46] use cyclic voltammetry and Daws et al. [47] use
high speed chronoamperometry. Bunin et al. studied release and reuptake of 5-HT in
rat brain slices after stimulation with electrical pulses at different frequencies. After sti-
mulation for 1/5 of a second at 100 Hz, the extracellular 5-HT concentration in the
dorsal raphe nucleus (DRN) rises to about 1.8 μM and then declines rapidly back to
baseline with half life of about 1 second (their Figure six). In the presence of 10 μM
fluoxetine, the extracellular 5-HT rises slightly higher and declines to baseline with a
half-life of 2 seconds. We represent their stimulation in our model neuron by raising
fire from 1 to 5000 for 1/5 of a second. The results can be seen in Figure 3. Extracellu-
lar 5-HT rises to 2 μM and then decays back to baseline with a half-life of 1 second
(blue curve). We modeled the presence of fluoxetine by blocking half the SERTs. In
that case the extracellular 5-HT curve rises slightly higher and decays back to baseline
with a half-life of about 2 seconds. Notice that the decay curves do not look exponen-
tial. In fact, they are linear until the concentration of extracellular 5-HT gets fairly low.
This is because at 1-2 μM the extracellular 5-HT concentration is well above the Km of
the SERTs so the SERTs are saturated and pumping at a constant rate. The same effect
can be seen in Figure six of [46]. The decay time back to baseline depends of course
on the Vmax of the SERTs, which in turn depends on the SERT density that is quite
different in different brain regions. Daws et al. [47] examined several different brain
regions and found much longer half-lives than reported in [46], probably because
those regions have much lower SERT densities. This difference may also be due to the
fact that 5-HT is applied exogenously in the brains of anesthetized rats in [47] while in
[46] tissue slices are stimulated by electrical pulses.
C. SERT Knockouts
A large number of studies have examined the pharmacological and behavioral charac-
teristics of mice that have the SERT gene knocked out. Such knockouts are of particu-
lar interest because they are an (extreme) model of what one could expect with high
doses of SSRIs that block the SERTs. Table 4 shows steady state concentration and
velocities for WT mice (left column) and steady state concentrations and velocities for
SERT knockout mice (right column) in the model. Each column shows the steady state
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for SERT knockout mice f = 0. The intervening columns corresponds to the effects of
progressively higher doses of SSRIs as one moves from left to right.
It is known that 5-HT tissue levels are down both in knockouts [98] and in WT
mice treated with fluoxetine [99]. Homberg et al. [98] found that tissue levels of 5-HT
drop by 50-70% and Bengel et al. [100] found decreases of 60-80%. In our model, vesi-
cular 5-HT (the main determinant of tissue 5-HT) drops from 21.5 μMi nW Tt o6 . 4 1
μM in SERT knockouts corresponding well to these experimental results. Homberg
et al. also found that 5-HIAA tissue levels decrease 45-55%; in our model, where we
have a very simple model of 5-HIAA metabolism, levels decrease by 88%.
Table 4 Steady State Values from WT to SERT KO
f * = 1(WT) f =. 5 f =. 2 f =. 1 f = .05 f = 0(SERT KO)
trp 20.1 20.9 21.1 21.1 21.2 21.3
c5-HT 0.5 0.39 0.3 0.25 0.19 0.05
v5-HT 21.5 19.9 18.1 17.05 14.67 6.41
e5-HT ** .7 1.18 1.82 2.26 3.32 6.2
5-hiaa 5.3 4.12 3.13 2.7 1.99 0.63
VTPH 5.57 4.59 3.86 3.6 3.32 3.12
VMAT 21.4 16.7 10.7 7.09 5.87 2.56
VSERT 21.1 16.2 9.93 6.16 4.5 0.0
Vrem 0.31 0.47 0.73 0.9 1.33 2.50
V
catab 5.26 4.12 3.13 2.7 1.99 0.63
* f is the fraction of SERTs that are functional.
** concentration in nM, all other concentrations in μM. Velocities have units μM/hr.
Figure 3 Release and reuptake. The time course of extracellular 5-HT is shown for a model experiment
where the neuron was stimulated for 1/5 of a second (blue curve). In the presence of fluoxetine, the time
course goes slightly higher and the decay time back to baseline doubles (green curve). We modeled the
presence of fluoxetine by blocking half the SERTs. The curves are very similar to those in Figure six of [46].
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dinov and Caron [12] report that extracellular 5-HT rises 5-6 fold in SERT knockouts
and Homberg et al. report a 9-fold increase [98]. In our model, extracellular 5-HT
rises to 6.2 μM from .768 nM, a 9-fold increase. We note that, in the model, extracel-
lular 5-HT already rises substantially when only 50% of the SERTs are active. On the
other hand, vesicular 5-HT remains almost normal when only 50% of the SERTs are
active, decreasing from 21.5 μM to 19.9 μM. This corresponds well with the finding of
Bengel et al. [100] that SERT knockout heterozygotes had almost normal tissue levels
of 5-HT.
In our model of a 5-HT terminal, we made the SERT knockout terminal by simply
setting the Vmax of VSERT equal to zero. The reality is much more complicated. SERT
knockout mice have been that way all their lives and one would expect that other
aspects of their serotonergic systems have also changed. SERT knockouts show devel-
opmental changes in neurons and brain, an impaired hypothalamic-pituitary-adrenal
axis, and desensitization of 5-HT1A and other receptors [101,102].
D. Homeostatic effects of the autoreceptors
It has been suggested that autoreceptors provide a kind of end product inhibition that
tends to stabilize extracellular 5-HT [1,103]. If extracellular 5-HT goes up, synthesis
and release go down; if extracellular 5-HT goes down, synthesis and release go up.
Indeed, Panel A of Figure 4 shows that extracellular 5-HT increases and decreases
with the tonic firing rate, but the increase and decrease is much less in the presence of
the autoreceptors. Thus the autoreceptors help to stabilize extracellular 5-HT in indivi-
duals against changes in inputs to the system like changes in firing rate or changes in
mean blood tryptophan level (not shown).
However, the autoreceptors provide another kind of homeostasis, too. The genes for
many of the enzymes and transporters in the serotonergic system have common poly-
morphisms in different human populations. Many of these polymorphisms are known
to be functional in that they change the activity of the corresponding enzymes or the
efficacy of the transporters. The autoreceptors tend to keep these serotonergic systems
functioning normally despite the polymorphisms.
Polymorphisms in the SERT gene have been associated with depression and other
mood disorders [10,11,13]. The SERT gene has a polymorphic regulatory region (the
Figure 4 Homeostatic effects of the autoreceptors.P a n e lAs h o w sh o w se x t r a c e l l u l a r5 - H T( e5ht)
changes as the firing rate of the neuron varies above and below normal both with and without the
autoreceptors. Panel B shows how extracellular 5-HT changes with the expression level of the SERTs both
with and without the autoreceptors. s/s and l/l indicate the activities of the corresponding genotypes.
Panel C shows how extracellular 5-HT changes with the activity level of TPH both with and without the
autoreceptors. The activities of the R441 H and P449R polymorphims are indicated. In all cases, the
autoreceptors reduce the effect of changes in firing rate and polymorphisms on extracellular 5-HT.
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dem repeat: the short allele has 14 repeats, whereas the long allele has 16 repeats. The
short allele reduces transcriptional activity of the gene and results in decreased expres-
sion of the serotonin transporter. The transcriptional activity of the short (s) allele is
about 1/3 of that of the long (l) allele [14]. Although the level of transcription of a
gene does not necessarily correspond to the activity of its product, we will assume that
SERT activity in a s/s homozygote is 1/3 that in the l/l genotype. A study of 505 sub-
jects [14] revealed that in a population sample of 505 individuals, 19% were of the s/s
genotype, 49% were l/s, and 32% were l/l. Thus heterozygotes are the most common
genotype, and if we assume their SERT activity is 1.0, then the activity of the s/s geno-
type would be 0.5 and of the l/l genotype 1.5. Panel B of Figure 4 shows that varying
SERT activity over this range has a large effect (.5 μMt o1 . 6μM) on the extracellular
5-HT concentration if the autoreceptors are turned off and a much smaller effect (.6
μM to 1.1 μM) if the autoreceptors are turned on.
There are several functional polymorphisms in the TPH2 gene and some are asso-
ciated with the risk of bipolar disorder [19]. The SNP C2755A changes the amino acid
from serine to tyrosine at peptide position 41; the tyrosine coding allele reduces the
activity of TPH2 by about 35% [19]. A genetic polymorphism of the promoter,
rs11178997, reduces TPH2 transcriptional activity by 22% [104]. The R441 H mutation
of TPH2 codes for an enzyme that has only 19% of the wild type activity and the
P449R mutation has an activity of 65% of wild type [105]. Thus genetic variation in
human populations can cause variation of TPH2 activity between 0.19 and 1.0 of nor-
mal. Panel C of Figure 4 shows that varying TPH2 activity over this range has signifi-
cant effect on the extracellular 5-HT concentration but the effect is less in the
presence of the autoreceptors.
As can be seen, the autoreceptors significantly reduce the variation in extracellular
serotonin caused by polymorphisms in TPH and SERT.
E. Interaction of autoreceptors and SERTs
Many investigators have studied the effects of doses of SSRIs on extracellular 5-HT in
different brain regions. A particular focus of these studies has been to understand the
role of the autoreceptors. We have conducted experiments with our model that corre-
spond to some of the experiments in [106-109].
Casanovas et al. [108] measured the extracellular 5-HT in the frontal cortex and the
hippocampus in the rat after applying doses of 5-HT1A autoreceptor agonists. They
found a rapid decline in the frontal cortex to about 30% of basal values and a decline
in the hippocampus to about 70% of basal values. These effects are attributed to the
stimulation of the 5-HT1A autoreceptors on cells in the raphe since it is known that
such stimulation substantially decreases the firing rate of the serotonergic neurons in
the raphe that project to the frontal cortex and the hippocampus. The dorsal raphe
(DRN) projects to the frontal cortex and the median raphe (MRN) projects to the hip-
pocampus. Casanovas et al. attribute the greater decline in the frontal cortex to the
fact the density of 5-HT1A autoreceptors is higher in the DRN than the MRN [110],
and therefore firing is reduced much more in the DRN than in the MRN.
In Figure 4, we see that, in the model, a reduction of fire to 58% of normal causes a
reduction of extracellular 5-HT at steady state to 70% of normal. Therefore, to
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pocampus we lowered fire in a time-dependent manner to 58% of normal and then let
it recover. Similarly, a reduction of fire to 20% of normal causes a reduction of extra-
cellular 5-HT at steady state to 30% of normal. Therefore, to simulate the effect of a
dose of a 5-HT1A agonist on the extracellular 5-HT in the frontal cortex we lowered
fire in a time-dependent manner to 20% of normal and then let it recover. The effects
on extracellular 5-HT in the frontal cortex and hippocampus can be seen in Panel A
of Figure 5. These curves are very similar to those in Figure one (a, b) of Casanovas et
al.[108]. The extracellular concentrations of 5-HT decrease in the frontal cortex and
hippocampus because the firing rates in the DRN and the MRN are reduced due to
the binding of the agonist to the autoreceptors on cell bodies. The concentrations of
5-HT in the frontal cortex and hippocampus begin to recover after the initial decline
because the terminal autoreceptors in the frontal cortex and hippocampus increase
synthesis and release of 5-HT.
Malagie et al.[106] administered fluoxetine to anaesthetized rats and measured
extracellular 5-HT in the frontal cortex and hippocampus. This is a very interesting
experiment because fluoxetine blocks SERTs in the DRN and MRN and thus extracel-
lular 5-HT will rise, stimulating the 5-HT1A autoreceptors and decreasing firing as in
the experiments Casanovas et al.[107,108]. This effect will tend to lower extracellular
5-HT in projection regions. However, fluoxetine will also block SERTs in the projec-
tion regions, which tends to raise extracellular 5-HT there. Thus, in the projection
regions the level of extracellular 5-HT reflects a balance between these two effects. To
see what the balance is in our model, we represent a dose of fluoxetine as described
under “fluoxetine dosing” in Methods, and assume that fire drops as a function of time
in the DRN and MRN as indicated above in the discussion of the experiments of Casa-
novas et al.. The results are shown by the blue (frontal cortex) and green (hippocam-
pus) solid curves in Figure 5B. Hippocampal extracellular 5-HT rises by approximately
147% and frontal cortex extracellular 5-HT rises approximately 63%. These curves are
very similar to the analogous curves in Malagie et al., Figure one (the 10 mg/kg dose),
where extracellular 5-HT rises about 110% in the hippocampus and 60% in the frontal
cortex. In a second study, Malagie et al.[109] performed similar experiments with
Figure 5 Effects of 5-HT1A agonists and fluoxetine. Panel A shows the change in extracellular 5-HT in
the hippocampus and the frontal cortex computed by the model after a 5-HT1A agonist is given. The
curves are similar to those in [108]. Panel B shows model computations of the extracellular concentrations
of 5-HT in the hippocampus and the frontal cortex after a dose of an SSRI (fluoxetine or paroxetine); the
solid curves are wild type and the dashed curves are 5-HT1B knockouts. These curves should be compared
to Figure one (10 mg/kg dose) in [106] and Figure one (a, b, c, d) in [109]. For discussion, see the text.
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out. They saw a large increase in hippocampal extracellular 5-HT and a smaller rise in
frontal cortex extracellular 5-HT compared to wild type. In the model we make a 5-
HT1B knockout by simply turning off the terminal autoreceptors. The results can be
seen in the blue (frontal cortex) and green (hippocampal) dashed curves in Figure 5B.
The model hippocampal extracellular 5-HT concentration rises 369% in the knockout,
compared to 147% in wild type mice. The model frontal cortex extracellular 5-HT
rises 82% as compared to 63% for the wild type. The model curves should be com-
pared to those in Malagie et al. (Figure one,a,b,c,d ). They gave two doses (1 mg/kg
and 5 mg/kg). Our model results are simlar to their results but with larger changes
than those induced by their 1 mg/kg dose and smaller changes than than those
induced by their 5 mg/kg dose. This indicates that our “dose” is between their doses.
As they saw, we also found that the knockout induced smaller changes in the frontal
cortex than in the hippocampus. Notice that in all cases, there is an increase in extra-
cellular 5-HT caused by the blockage of SERTs. But this effect is then moderated by
the increased rate of removal and catabolism, which slowly bring the extracellular con-
centrations back to equilibria (that are higher than prior to the dose of fluoxetine).
Discussion
We have presented a relatively simple and straightforward model of synthesis, release,
and reuptake of 5-HT in a serotonergic terminal. The kinetics for individual reactions
and the values of constants were chosen as much as possible from the experimental lit-
erature. The purpose is to create a model that can be used, here and in future investi-
gations, as a platform for exploring various hypotheses about serotonergic homeostasis
and serotonergic signaling. Some results and predictions of the model have already
appeared in [40]. We note that we have not altered parameters and kinetics to fit any
particular set of experimental data. The parameter values remain the same in all the
model experiments in the Results sections, except as indicated for changes correspond-
ing to the particular experimental situations that we were examining.
Any model includes many oversimplifications. We have not included the details of
the use of tryptophan in other metabolic pathways. The processes by which vesicles
are created, move to the synapse, and release their serotonin are complicated and
interesting [67,70-72], but are not included in this model. In our model the SERTs put
released serotonin back into the terminal, but we do not include leakage of cytosolic
serotonin through the SERTs into the extracellular space. We include in the model the
effects of the terminal autoreceptors on serotonin synthesis (via TPH) and on seroto-
nin release, but we do not include effects of autoreceptors on reuptake [74]. In this
f i r s tm o d e lw eh a v en o ti n c l u d e dt h es o m ae x plicitly, so the effects of the somatic
autoreceptors are modeled by directly affecting firing rate and thus release in the
terminal.
In Section A of Results we use the model to give reasons for the well known obser-
vations that dopamine synthesis is relatively insensitive to tyrosine availability, but ser-
otonin synthesis is quite sensitive to tryptophan availability[1,93,94]. First, at the
normal intracellular concentration of DA, the TH reaction is already running close to
saturation, however the normal intracellular concentration of tryptophan is well below
the Km of TPH, so changes in availability cause big changes in synthesis rate. Second,
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in the case of tryptophan than in the case of tyrosine. We showed (Figure 2) the con-
sequences of these differences for the time-dependent behavior of extracellular DA and
5-HT due to meals. In our model calculations, for simplicity, we assumed that the
transport of the amino acids tyrosine and tryptophan across the blood brain barrier are
independent of each other. In fact, both tyrosine and tryptophan compete for the L-
transporter [55] with many other amino acids including the branched chain amino
acids (BCAA). The protein composition of meals affects how much tyrosine and tryp-
tophan is imported into the brain and thus how much brain DA and 5-HT change
[54,95,111,112]. Even more interesting, Fernstrom[24] has shown that the order of
meals affects how much tryptophan gets into the brain. The reason is that carbohy-
drate meals stimulate insulin production and this tends to transport amino acids into
skeletal muscle, but tryptophan is partially protected from this transport because it is
bound to serum albumin. A mathematical model for these competitive transport pro-
cesses is in preparation.
In Section B of results we examine the time courses of extracellular 5-HT after an
electric shock both with and without the presence of fluoxetine. Our time courses are
very similar to those found in [46] for the DRN and substantia nigra reticulata. The
shapes of the curves depend heavily on the density of SERTs, which is known to vary
by a factor of 5 in different projection regions [113]. Thus, much slower uptake was
found in the dentate gyrus, the corpus callosum and the CA3 region of the hippocam-
pus [47]. This is a good reminder that there is no such thing as a single model of “the“
serotonergic terminal. Parameters, both SERT density and also expression levels of
5-HT1A receptors [22], can vary by large amounts in different projection regions,
presumably for important functional reasons.
In Section C we examined the steady state concentrations and velocities in the model
corresponding to different densities of SERTs, or, equivalently, different doses of SSRIs
that block the SERTs. The case where the SERTs are completely blocked corresponds
to SERT knockout mice. The model concentrations of extracellular 5-HT and vesicular
5-HT are similar to those found in experiments of SERT knockout mice. Extracellular
5-HT is up 9-fold and vesicular 5-HT is down 70%. Interestingly, as more and more
SERTs are blocked corresponding to higher and higher doses of fluoxetine, vesicular 5-
HT decreases fairly slowly (Table 4). It is known [99] that tissue levels of 5-HT do
decrease in the presence of SSRIs, but this decrease has not been remarked on very
much in the literature, perhaps because it is a relatively moderate effect as predicted
by our model.
In Section D we examined the steady state effects of the autoreceptors and showed
that they produce two kinds of homeostasis. First, they moderate the effects of changes
in the cell’s environment on the concentration of extracellular 5-HT. We illustrate this
by changing the firing rate (Figure 4, Panel A), but similar moderating effects are seen
with changes in tryptophan availability or MAO activity. Thus, the autoreceptors allow
serotonergic signaling to continue more or less as before in the face of a changed
environment. Second, the autoreceptors partially compensate for the effects of various
polymorphisms in the genes for TPH and SERTs (Figure 4, Panels B and C). Even
though a polymorphism reduces the activity of TPH by 50%, the vesicular and extracel-
l u l a r5 - H Td e c r e a s eb yo n l y1 3 %( P a n e lC ) .T h u s ,t h ea u t o r e c e p t o r sg i v eak i n do f
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calculations that show quantitatively the importance of this aspect of autoreceptor
function.
Finally, in Section E we conducted model experiments that correspond to experi-
ments in which the time course of extracellular 5-HT was measured in different brain
regions of animals after a dose of an SSRI. The purpose of many of these experiments
was to investigate functional effects of the somatodendritic (5-HT1A) autoreceptors or
the terminal (5-HT1B) autoreceptors, so the experiments were carried both in and
without the presence of autoreceptor antagonists. In general, our model calculations
correspond reasonably well to the experimental results and give some insight into the
reasons why the experimental results look the way they do. We note that autoreceptor
densities vary considerably in different brain regions [9,25,22], and this variation is
likely to have important electrophysiological and behavioral consequences.
Other results of this model have been published previously. It is known that seroto-
nergic neurons in the DRN fire tonically at frequencies of 0.4-2.5 spikes/second and
that they also fire short bursts at higher frequencies that convey sensory or motor
information [1]. In [40] we showed that the model rersponse to burst firing is very
dependent on the density of SERTs on the terminal, which is proportional to the Vmax
of VSERT. The size of this Vmax determines how long it takes to clear the extracellular
space of excess 5-HT after a spike. If this clearance time is approximately the time
between spikes during tonic ring, then even a short burst will raise extracellular 5-HT
considerably. However, if this clearance time is very short, for example, 1/3 of the time
between spikes in tonic firing, then a burst of three spikes at triple the tonic frequency
raises extracellular 5-HT little. It is known that the density of SERTs varies by about a
factor of five across different projection regions [46,47,113]. Interestingly, the frequency
of tonic firing of serotonergic cells in the dorsal raphe nucleus also varies by about a
factor of four or five [1,114,115]. This led us to predict that the SERT density in pro-
jection regions is tuned to the tonic firing rate of the DRN cells that project to that
region, where “tuned” means that the clearance time is approximately the interspike
interval for tonic firing. If it is possible to determine experimentally how the tonic
firing rates of DRN cells relate to the region they project to, this prediction can be
confirmed or refuted.
The fact that the mathematical model presented here is only for a serotonergic term-
inal limits our ability to address important issues involving mechanisms at the soma of
serotonergic cells and their influence on extracellular 5-HT at terminals in projection
regions. The serotonergic cells in the DRN and MRN release 5-HT from both the
soma and dendrites and only 70% of the release is related to firing[25,116,117]. SSRIs
block SERTs on these cell bodies as well as on terminals in projection regions, raising
extracellular 5-HT in the DRN and MRN and decreasing firing rate via the 5-HT1A
autoreceptors[107,118]. Thus, acute use of SSRIs can have two conflicting conse-
quences in terminal regions: increased extracellular 5-HT because of SERT blockage
on the terminal, and decreased extracellular 5-HT because of SERT blockage on the
cell bodies. A common hypothesis is that chronic use of SSRIs does not have a thera-
peutic effect for several weeks because it takes that long for the 5-HT1A autoreceptors
on cells bodies to desensitize[25,31,119]. While this hypothesis may have merit, addi-
tional factors such as SERTs are also likely to be involved. Studies have shown
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possible that the dynamic time scale of such SERT downregulation may contribute to
the delay period. An increase in extracellular DA rapidly recruits more DATs to the
terminal membrane, but downregulation of DAT activity and density follows as the
increase becomes chronic[120]; similar dynamic regulation of SERTs is possible, both
at the soma and at terminals. In order to examine the interplay between 5HT1A recep-
tors and dynamic SERT regulation in the presence of SSRIs, we plan to extend our
model to include the cell body of the serotonergic cell.
It is worthwhile to keep in mind how difficult the study of the serotonergic system
really is. Though much new information is available that gives associations between
genotypes and behaviors, the causal mechanisms are mostly unknown. These casual
mechanisms necessarily involve cell biochemistry and morphology and the connections
between the biochemistry and morphology and the electrophysiology of neurons and
networks of neurons. Even more daunting is the fact that the four levels, gene expres-
sion, biochemical, electrophysiological, and behavioral, influence each other, both
chronically and dynamically. Experiments are often difficult to interpret because
changes at more than one level may be involved. In this situation, mathematical mod-
els based on real physiology can contribute to understanding, for they provide a plat-
form for testing hypotheses and investigating how changes, chronic or dynamic, at one
level cause changes at the other levels.
Conclusions
Serotonergic systems must respond robustly to important biological signals, while at
the same time maintaining homeostasis in the face of normal biological fluctuations in
inputs, expression levels, and firing rates. Our mathematical model gives insight into
how this homeostasis is accomplished through the cooperative effect of many different
homeostatic mechanisms including the special properties of tryptophan hydroxylase,
the serotonin reuptake transporters, and the serotonin autoreceptors. The model also
shows how the autoreceptors moderate the effects of polymorphisms in the genes for
the SERTs and TPH. The model calculations correspond quite well to a variety of
experimental data. Thus, the model can be useful for testing hypotheses about the rela-
tionships between gene expression, biochemistry, and serotonergic signaling.
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